By Connor Hart
Shares of NeoGenomics fell to their lowest price in more than two years after the company widened its net loss of the fourth quarter and guided for continued unprofitably in the current year.
The stock sank 23%, to $11.11, in early afternoon trading Tuesday. Shares are down 32% since the beginning of the year.
Before the bell, the oncology testing-services company reported a net loss of $15.3 million, or 12 cents a share, compared with a loss of $14.3 million, or 11 cents a share, a year earlier.
Adjusted per-share earnings came in at 4 cents, just ahead of the 3 cents that analysts surveyed by FactSet expected.
Revenue increased 11% to $172 million but missed the $173.2 million that Wall Street had modeled.
Chief Executive Chris Smith, who is set to retire on April 1, said he believes the company is well positioned for long-term growth, citing its upcoming product launches and focus on disciplined capital deployment.
In 2025, the company guided for a loss of $85 million to $76 million, missing analyst views for a loss of $56.5 million. Its top-line outlook of $735 million to $745 million came in ahead of the $733.1 million that analysts were looking for.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
February 18, 2025 13:17 ET (18:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。